This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of -17.65% and 3.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Blueprint Medicines (BPMC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Adaptive Biotechnologies (ADPT) and Avanos Medical (AVNS) have performed compared to their sector so far this year.
Philips (PHG) Drives Healthcare Prospects With Enhanced Dataset
by Zacks Equity Research
Philips (PHG) announces its expansion with MIT IMES, which will help researchers and educators access a new critical care dataset.
Philips (PHG) Inks 7-Year Partnership With Northwell Health
by Zacks Equity Research
Philips (PHG) announces that it has entered into a seven-year agreement with Northwell Health, one of the largest healthcare providers in the state of New York.
Philips (PHG) Drives Health Care Prospects With New Solutions
by Zacks Equity Research
Philips (PHG) announces Philips Virtual Care Management solutions, which provide a comprehensive approach to telehealth for patients, providers and payers.
Is Fulgent Genetics (FLGT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Fulgent Genetics, Inc. (FLGT) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.
Sanofi's (SNY) Dupixent Meets Goal in Pivotal COPD Study
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron's (REGN) Dupixent led to a 30% decline in exacerbations per a late-stage pivotal study on chronic obstructive pulmonary disease.
BridgeBio Pharma (BBIO) Surges 77% YTD: Here's Why
by Zacks Equity Research
Shares of BridgeBio (BBIO) are up rising since the company announced positive data from a mid-stage study, which evaluated its experimental drug infigratinib in children with achondroplasia, a form of dwarfism.
Karuna's (KRTX) KarXT Meets Primary Goal in Schizophrenia Study
by Zacks Equity Research
Data from a late-stage study shows that treatment with Karuna's (KRTX) lead candidate, KarXT, led to an early and sustained statistically significant reduction of symptoms of schizophrenia.
Esperion (ESPR) Plummets 54% Over Milestone Payment Row
by Zacks Equity Research
An SEC filing by Esperion (ESPR) reveals that partner Daiichi Sankyo disagrees with the company's assessment that cardiovascular outcome CLEAR study data would support milestone payments.
Merck's (MRK) Co-formulation Therapy Fails Lung Cancer Study
by Zacks Equity Research
Data from a mid-stage study showed that Merck's (MRK) MK-7684A did not improve progression-free survival as a potential treatment for patients with metastatic non-small cell lung cancer.
Bellicum (BLCM) Down on Ending Development of CAR-T Candidates
by Zacks Equity Research
Following the decision to discontinue the development of pipeline candidates, Bellicum Pharmaceuticals (BLCM) is left with no candidate in clinical development. The stock is down 50% post the news.
Jounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciences
by Zacks Equity Research
Jounce Therapeutics (JNCE) receives a proposal from Concentra Biosciences to acquire 100% equity stake in the company.
Neoleukin (NLTX) Up 36% on Initiating Another Restructuring Plan
by Zacks Equity Research
Neoleukin (NLTX) seeks strategic options to maximize shareholder's value. This includes the undertaking of another restructuring plan to reduce 70% of the existing workforce.
AstraZeneca (AZN) Posts Positive Data From Lung Cancer Studies
by Zacks Equity Research
Data from late-stage label expansion studies show that AstraZeneca's (AZN) cancer drugs are effective for treating non-small cell lung cancer indications.
How Much Upside is Left in Adaptive Biotechnologies (ADPT)? Wall Street Analysts Think 49.94%
by Zacks Equity Research
The consensus price target hints at a 49.9% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is Fulgent Genetics (FLGT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Fulgent Genetics, Inc. (FLGT) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.
BioMarin (BMRN) Provides FDA Filing Update for Gene Therapies
by Zacks Equity Research
The FDA accepts BioMarin's (BMRN) label-expansion filing for Voxzogo to treat children under five years with achondroplasia. The agency extends the review period for Roctavian BLA.
Emergent's (EBS) Q4 Earnings Miss, Sales Beat Estimates
by Zacks Equity Research
Emergent (EBS) reported mixed fourth-quarter 2022 results. While the company significantly misses the mark on earnings, it beat sales estimates.
Perrigo (PRGO) Beats Q4 Earnings Estimates, Lags on Sales
by Zacks Equity Research
Perrigo (PRGO) reports mixed fourth-quarter 2022 results. While the company beats the mark on earnings, it misses sales estimates.
Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Karuna Therapeutics (KRTX) reports encouraging fourth-quarter 2022 results. The company beats estimates for earnings and sales.
Can Adaptive Biotechnologies (ADPT) Climb 45.58% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in Adaptive Biotechnologies (ADPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.